Hrt Financial LP Altimmune, Inc. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $690,377 - $2.77 Million	164,768 New	164,768 $695,000
Q2 2022 Aug 12, 2022	SELL	$3.94 - $11.77 $876,129 - $2.62 Million	-222,368 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $1.31 Million - $2.1 Million	222,368 New	222,368 $1.35 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $537,386 - $898,008	-54,557 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $557,308 - $1.07 Million	43,848 Added 409.45%	54,557 $770,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $83,958 - $152,281	10,709 New	10,709 $120,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.